1 in 4 Medicare beneficiaries with obesity could get Wegovy despite coverage ban
- Approximately 3.6 million Medicare enrollees qualify for coverage of anti-obesity drug Wegovy, potentially costing Medicare close to $3 billion annually, according to a KFF analysis.
- Medicare allowed Part D drug plans to cover Wegovy for overweight or obese beneficiaries with heart disease history after FDA approval.
- 7% of Medicare enrollees meet the criteria for Wegovy coverage, with potential high monthly co-insurance costs noted by KFF.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left0Leaning Right0Center22Last Updated10 days agoBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
